ENSC — Ensysce Biosciences Income Statement
0.000.00%
- $3.30m
- -$0.19m
- $2.23m
- 39
- 44
- 24
- 28
Annual income statement for Ensysce Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 3.53 | 2.52 | 2.23 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.33 | 1.37 | 23.4 | 30.7 | 12.9 |
Operating Profit | -3.33 | -1.37 | -19.9 | -28.2 | -10.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.921 | 4.56 | -29.1 | -24.2 | -10.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.366 | 4.31 | -29.1 | -24.2 | -10.6 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 0.366 | 4.31 | -29.1 | -24.2 | -10.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.366 | 4.31 | -29.9 | -25.1 | -10.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 14.4 | 156 | -356 | -117 | -4.69 |